FGF21 and metabolic dysfunction-associated steatohepatitis: However, in the lipotoxic mechanistic models (MCD, CDA-HFD) with a higher degree of inflammation and fibrosis, FGF21 treatment improved all parameters of importance in NASH, without lowering BW in the MCD model (97, 106, 112, 113).